Skip to main content
eXit

ImmunoSensation leaves X

Due to recent developments, we decided to discontinue our activities on the social media plattform X. With this decision, we follow more than 60 german universities and other research institutions. As a Cluster of Excellence, we see the communication of research and scientific results as well as their discussion as one of our tasks, which is why we did not make this decision lightly. However, X's line is not compatible with the basic values that we represent and also want to live in our communication. These include transparency, constructive discourse and, above all, scientific integrity.

We are looking forward to welcome you on our channels at

Bluesky

LinkedIn

Instagram

facebook

youtube

 

Related news

25 Millionen Euro für die Bonner KI-Krebsforschung: (v.l.) Prof. Dr. Bernd Weber, Prof. Dr. Michael Hölzel, Prof. Dr. Jürgen Bajorath und Prof. Dr. Uwe Reuter, beim Auftakt von AI4CancerCure.NRW in der Staatskanzlei Nordrhein-Westfalen.

Honors & Funding

€25 Million for AI-Powered Cancer Research in Bonn

—University Hospital Bonn (UKB), the University of Bonn and the Lamarr Institute for Machine Learning and Artificial Intelligence are using funding from the state of North Rhine-Westphalia to establish a joint research infrastructure. The aim is to use AI to design and optimize potential cancer therapeutics and subsequently test them in the laboratory. Minister-President Hendrik Wüst and Minister of Science Ina Brandes presented the funding commitment today at the State Chancellery of North Rhine-Westphalia.
View entry
Prof. Christian Strassburg, Direktor der Klinik für Allgemeine Innere Medizin am UKB, mahnt: „Die Abnehmpille ist nicht einfach nur irgendein Spaßfaktor, um jetzt ein bisschen abzunehmen!“

Publication

Weight-Loss Pill Instead of Injection: Finally, an Easy Way to Lose Weight?

—As of September 1, semaglutide will be available in Germany for the treatment of overweight and obesity in tablet form for the first time. The therapy, previously known primarily as a “weight-loss injection,” can now also be taken orally. The market launch is likely to attract considerable interest – but anyone considering treatment should be aware of one thing first: the tablet is not a way to lose a few kilos, but a prescription medication for the treatment of a chronic disease.
View entry
Prof. Matthias Geyer, - together with Prof. Robert P. Fisher from New York, provides an overview of the current state of research on the transcriptional regulation of cyclin-dependent kinases (CDKs) and the prospects for cancer treatment.

Publication

A Ray of Hope in the Fight Against Cancer

—Cancer is the second leading cause of death in Germany. In the search for new therapeutic approaches that target the uncontrolled growth of tumor cells, a class of enzymes known as cyclin-dependent kinases (CDKs) has come into focus. This is because this family of enzymes plays a fundamental role in gene expression and cell division. An overview of the current state of research on the transcriptional regulation of CDKs and the prospects for cancer treatment was compiled by Prof. Matthias Geyer of the UKB in collaboration with Prof. Robert P. Fisher and has now been published.
View entry

Back to the news overview